Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 9;75(3):656–667. doi: 10.1093/jac/dkz502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — HIV pretreatment drug resistance (PDR) prevalence in the Mexico City metropolitan area, 2016–18. HIV drug resistance was estimated using next-generation sequencing from 2447 persons starting first-line ART, diagnosed at the Condesa Clinic. (a) HIVDR prevalence by drug class. (b) HIVDR prevalence by antiretroviral drug. Lines represent 95% CI. (c) DRM frequency at different sensitivity thresholds; only surveillance mutations are shown (Stanford HIV Drug Resistance Database). EFV, efavirenz; NVP, nevirapine; RPV, rilpivirine; ETR, etravirine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ATV/r, atazanavir boosted with ritonavir; LPV/r, lopinavir boosted with ritonavir; DRV/r, darunavir boosted with ritonavir; FPV/r, fosamprenavir boosted with ritonavir; IDV/r, indinavir boosted with ritonavir; NFV, nelfinavir; SQV/r, saquinavir boosted with ritonavir; TPV/r, tipranavir boosted with ritonavir; DTG, dolutegravir; EVG, elvitegravir; RAL, raltegravir; INSTI, integrase strand-transfer inhibitor. ^aConsidering EFV, NVP, any NRTI, ATV/r, LPV/r, DRV/r, DTG, EVG and RAL.